WASHINGTON – Dr. Julie Adams has signed up to see what medical device and drug makers have reported to the government about her financial ties with their industries.
But Adams, an orthopedic surgeon at the University of Minnesota, is worried about her peers. A Sept. 10 deadline is approaching for physicians to check and challenge new disclosures that will become public as part of national health care reform.
"The burden is on physicians to correct the data," Adams said.
If they don't, it becomes public on Sept. 30 as part of the Physicians Sunshine Act, a law that applies to hundreds of thousands of doctors and roughly 1,100 teaching hospitals across the country. It is intended to allow patients to see monetary links between their doctors and device and drug companies. It aims to cut down on conflicts of interest that can affect treatment decisions.
But there are major challenges in assembling and validating the data. As times runs out to review the accuracy of the information, the U.S. Centers for Medicare and Medicaid Services (CMS) will not say how many individuals and institutions have signed up to review the data or how many have disputed it.
While registration is voluntary, participation by individual physicians is critical, officials at the University of Minnesota stress, because those who don't play could pay with an unnecessary hit to their image.
"Someone with a research grant would not want to see it reported as speaking fees," explained Dr. Mark Paller, a senior associate dean at the University of Minnesota medical school. "Those have totally different implications."
Many doctors in Minnesota have had to make private institutional disclosures about financial ties to industry for years. Medtronic, the state's largest medical device maker, began voluntarily disclosing financial ties to physicians on its website in 2010. Drug companies have also voluntarily reported financial ties to physicians to the state government for inclusion in a public database. But the Physicians Sunshine Act is a whole other level of transparency. Device and drugmakers must report to the federal government so-called "transfers of value" to doctors, osteopaths, dentists, podiatrists, optometrists and chiropractors of more than $10 in a single transaction and, cumulatively, more than $100 in a year.